ID   M321
AC   CVCL_D768
DR   cancercelllines; CVCL_D768
DR   Cosmic; 1425349
DR   Cosmic; 1459653
DR   Wikidata; Q54903595
RX   PubMed=20406486;
RX   PubMed=20689758;
CC   Doubling time: 34.1 hours (PubMed=20406486).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=20406486).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 12
//
RX   PubMed=20406486; DOI=10.1186/1479-5876-8-39; PMCID=PMC2876068;
RA   Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S.,
RA   Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N.,
RA   von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B.,
RA   Koya R.C., Mischel P.S., Lo R.S., Ribas A.;
RT   "Differential sensitivity of melanoma cell lines with BRAFV600E
RT   mutation to the specific Raf inhibitor PLX4032.";
RL   J. Transl. Med. 8:39.1-39.11(2010).
//
RX   PubMed=20689758; DOI=10.1593/neo.10414; PMCID=PMC2915408;
RA   Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G.,
RA   Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.;
RT   "Pharmacodynamic characterization of the efficacy signals due to
RT   selective BRAF inhibition with PLX4032 in malignant melanoma.";
RL   Neoplasia 12:637-649(2010).
//